Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 6;18(11):6131.
doi: 10.3390/ijerph18116131.

Quality of Life in Hidradenitis Suppurativa: An Update

Pavel V Chernyshov  1 , Andrew Y Finlay  2 , Lucia Tomas-Aragones  3 , Francoise Poot  4 , Francesca Sampogna  5 , Servando E Marron  6 , Sergey V Zemskov  7 , Damiano Abeni  5 , Thrasyvoulos Tzellos  8   9 , Jacek C Szepietowski  9   10 , Christos C Zouboulis  9   11
Affiliations
Review

Quality of Life in Hidradenitis Suppurativa: An Update

Pavel V Chernyshov et al. Int J Environ Res Public Health. .

Abstract

Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients' HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.

Keywords: biologics; hidradenitis suppurativa; impact; quality of life; surgery; treatment.

PubMed Disclaimer

Conflict of interest statement

C.C.Z. declares that none of the mentioned conflicts of interest had any influence to this manuscript. C.C.Z. has received thematically relevant honoraria from Incyte, Inflarx, Janssen-Cilag, Novartis, Regeneron and UCB as advisor. His departments have received grants from AbbVie, AOTI, Astra Zeneca, Galderma, Inflarx, Naos-Bioderma, Novartis, PPM and UCB for his participation as clinical investigator. J.C.S. served as a consultant and advisor for AbbVie, Leo Pharma, Novartis, Pierre-Fabre, Sienna Pharmaceuticals, Vifor and Trevi, investigator for AbbVie, Amgen, Janssen, Merck, Novartis, Regeneron, Trevi, Boehringer Ingelheim, Galapagos, InflaRX, Pfizer, UCB, Incyte, Helm, Janssen, Menlo Therapeutics and speaker for AbbVie, Janssen, Leo Pharma, Novartis, Sun-Farm, Eli Lilly and Sanofi-Genzyme. S.E.M. is a co-author of the HSQoL-24. T.T. is a speaker and member of the advisory board for Abbvie and UCB. A.Y.F. is joint copyright owner of the DLQI, CDLQI and FDLQI: Cardiff University receives royalties, A.Y.F. receives a share of these under standard university policy. A.Y.F. has served as a consultant to Novartis. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Number of publications on quality of life (QoL) in hidradenitis suppurativa (HS) per year in PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=hidradenitis%20suppurativa%2C%20quality%20of%20life; accessed on 2 April 2021).
See this image and copyright information in PMC

References

    1. Zouboulis C.C., Del Marmol V., Mrowietz U.U., Prens E.E., Tzellos T.T., Jemec G.B. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation. Dermatology. 2015;231:184–190. doi: 10.1159/000431175. - DOI - PubMed
    1. Jfri A., Nassim D., O’Brien E., Gulliver W., Nikolakis G., Zouboulis C.C. Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol. 2021 doi: 10.1001/jamadermatol.2021.1677. in press. - DOI - PMC - PubMed
    1. Zouboulis C., Bechara F., Dickinson-Blok J., Gulliver W., Horváth B., Hughes R., Kimball A., Kirby B., Martorell A., Podda M., et al. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization—systematic review and recommendations from the HS ALLIANCE working group. J. Eur. Acad. Dermatol. Venereol. 2018;33:19–31. doi: 10.1111/jdv.15233. - DOI - PMC - PubMed
    1. Zouboulis C.C., Benhadou F., Byrd A.S., Chandran N.S., Giamarellos-Bourboulis E.J., Fabbrocini G., Frew J.W., Fujita H., González-López M.A., Guillem P., et al. What causes hidradenitis suppurativa ?—15 years after. Exp. Dermatol. 2020;29:1154–1170. doi: 10.1111/exd.14214. - DOI - PubMed
    1. Zouboulis C., Da Costa A.N., Makrantonaki E., Hou X., Almansouri D., Dudley J., Edwards H., Readhead B., Balthasar O., Jemec G., et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2020;34:846–861. doi: 10.1111/jdv.16147. - DOI - PubMed

Substances